Bruker Management
Management criteria checks 4/4
Bruker's CEO is Frank Laukien, appointed in Feb 1991, has a tenure of 33.75 years. total yearly compensation is $5.86M, comprised of 15.8% salary and 84.2% bonuses, including company stock and options. directly owns 26.55% of the company’s shares, worth $2.06B. The average tenure of the management team and the board of directors is 10.6 years and 9.3 years respectively.
Key information
Frank Laukien
Chief executive officer
US$5.9m
Total compensation
| CEO salary percentage | 15.8% |
| CEO tenure | 33.8yrs |
| CEO ownership | 26.5% |
| Management average tenure | 10.6yrs |
| Board average tenure | 9.3yrs |
Recent management updates
Recent updates
Bruker's (NASDAQ:BRKR) Anemic Earnings Might Be Worse Than You Think
Nov 14
Bruker: Still Challenged, Certainly Margins
Nov 02Earnings Tell The Story For Bruker Corporation (NASDAQ:BRKR)
Oct 25We Think Bruker (NASDAQ:BRKR) Is Taking Some Risk With Its Debt
Sep 10Bruker: Multiple Risks And Declining Returns On Capital Aren't Priced In
Aug 22Is It Too Late To Consider Buying Bruker Corporation (NASDAQ:BRKR)?
Jul 22Bruker Corporation's (NASDAQ:BRKR) Business Is Yet to Catch Up With Its Share Price
Jun 09Bruker: A Confusing Acquisition Spree
May 31Bruker's (NASDAQ:BRKR) Promising Earnings May Rest On Soft Foundations
May 09Bruker Corporation: An Aggressive Acquisition Strategy
Apr 24Bruker Offers Upside With Key Enabling Technologies For Future Bio-Pharma Research
Apr 11Calculating The Fair Value Of Bruker Corporation (NASDAQ:BRKR)
Jan 22There's Reason For Concern Over Bruker Corporation's (NASDAQ:BRKR) Price
Jan 08Should You Be Adding Bruker (NASDAQ:BRKR) To Your Watchlist Today?
Dec 26Is Bruker Corporation (NASDAQ:BRKR) Potentially Undervalued?
Nov 06Is Bruker (NASDAQ:BRKR) Using Too Much Debt?
Oct 23Here's Why Bruker (NASDAQ:BRKR) Has Caught The Eye Of Investors
Sep 25Does This Valuation Of Bruker Corporation (NASDAQ:BRKR) Imply Investors Are Overpaying?
Aug 09Is Now The Time To Look At Buying Bruker Corporation (NASDAQ:BRKR)?
Jul 27Bruker (NASDAQ:BRKR) Has A Pretty Healthy Balance Sheet
Jul 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$305m |
| Jun 30 2024 | n/a | n/a | US$352m |
| Mar 31 2024 | n/a | n/a | US$402m |
| Dec 31 2023 | US$6m | US$926k | US$427m |
| Sep 30 2023 | n/a | n/a | US$319m |
| Jun 30 2023 | n/a | n/a | US$319m |
| Mar 31 2023 | n/a | n/a | US$312m |
| Dec 31 2022 | US$5m | US$873k | US$297m |
| Sep 30 2022 | n/a | n/a | US$275m |
| Jun 30 2022 | n/a | n/a | US$274m |
| Mar 31 2022 | n/a | n/a | US$282m |
| Dec 31 2021 | US$6m | US$812k | US$277m |
| Sep 30 2021 | n/a | n/a | US$270m |
| Jun 30 2021 | n/a | n/a | US$238m |
| Mar 31 2021 | n/a | n/a | US$204m |
| Dec 31 2020 | US$4m | US$689k | US$158m |
| Sep 30 2020 | n/a | n/a | US$158m |
| Jun 30 2020 | n/a | n/a | US$165m |
| Mar 31 2020 | n/a | n/a | US$177m |
| Dec 31 2019 | US$5m | US$753k | US$197m |
| Sep 30 2019 | n/a | n/a | US$207m |
| Jun 30 2019 | n/a | n/a | US$189m |
| Mar 31 2019 | n/a | n/a | US$184m |
| Dec 31 2018 | US$4m | US$731k | US$180m |
| Sep 30 2018 | n/a | n/a | US$98m |
| Jun 30 2018 | n/a | n/a | US$92m |
| Mar 31 2018 | n/a | n/a | US$84m |
| Dec 31 2017 | US$5m | US$704k | US$79m |
Compensation vs Market: Frank's total compensation ($USD5.86M) is about average for companies of similar size in the US market ($USD7.91M).
Compensation vs Earnings: Frank's compensation has been consistent with company performance over the past year.
CEO
Frank Laukien (64 yo)
33.8yrs
Tenure
US$5,858,761
Compensation
Dr. Frank H. Laukien, Ph D., serves as the Chairman, Chief Executive Officer and President of Bruker Corporation at Bruker BioSpin GmbH since February 1991. Dr. Laukien serves as the Chairman, Chief Execut...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 33.8yrs | US$5.86m | 26.55% $ 2.1b | |
| Executive VP & CFO | 6.7yrs | US$2.20m | 0.033% $ 2.5m | |
| Corporate Executive VP and President of Bruker Nano Group & Corporate | 9.3yrs | US$2.73m | 0.050% $ 3.9m | |
| President of Bruker CALID Group & Bruker Daltonics Division | 11.8yrs | US$1.47m | 0.081% $ 6.3m | |
| President of Bruker BioSpin Group | 6.5yrs | US$1.35m | 0.016% $ 1.2m | |
| Senior Director of Investor Relations & Corporate Development | no data | no data | no data | |
| General Counsel & Secretary | no data | no data | no data | |
| President and CEO of Bruker Energy & Supercon Technologies | 16.6yrs | US$967.91k | 0.0090% $ 698.4k |
10.6yrs
Average Tenure
62yo
Average Age
Experienced Management: BRKR's management team is seasoned and experienced (10.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 33.8yrs | US$5.86m | 26.55% $ 2.1b | |
| Independent Director | 9.3yrs | US$241.01k | 0.014% $ 1.1m | |
| Independent Director | 9yrs | US$224.01k | 0.019% $ 1.5m | |
| Independent Director | 17.5yrs | US$227.32k | 0.047% $ 3.7m | |
| Independent Lead Director | 24.8yrs | US$231.01k | 0.022% $ 1.7m | |
| Independent Director | 7.5yrs | US$224.01k | 0.013% $ 972.1k | |
| Independent Director | 9.3yrs | US$219.01k | 0.014% $ 1.1m | |
| Independent Director | 4.2yrs | US$219.65k | 0.0050% $ 392.7k | |
| Independent Director | 8.5yrs | US$216.83k | 0.0076% $ 594.2k |
9.3yrs
Average Tenure
66yo
Average Age
Experienced Board: BRKR's board of directors are considered experienced (9.3 years average tenure).